Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMD670 first-in-human placebo-controlled dose-escalation study in healthy volunteers and myasthenia gravis
NL-OMON54930Phase 1Active, not recruiting
- Sponsor
- NMD Pharma
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ignaseclant in myasthenia gravis (MG) (6 arms), sponsored by NMD Pharma. Primary endpoints: Serious adverse events and adverse events, Concomitant medication and 5 more. Started Jul 2020; status: active, not recruiting.
02
Drugs
ignaseclant
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON54930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54930.